News

News

NHRI Enters Technology Transfer Agreement of T-1501 (DBPR186) with Taivex Therapeutics Corp.

NHRI Enters Technology Transfer Agreement of T-1501 (DBPR186) with Taivex Therapeutics Corp.

National Health Research Institutes (NHRI) and Taivex Therapeutics Corp (Taivex) have signed the technology transfer agreement in September, 2021. Taivex has granted the exclusive rights of the small molecule Mertansine conjugate, DBPR186, with global patents.

About DBPR186
Phospholipid phosphatidylserine (PS), abundant on the external surfaces of cancer cells, is an established target molecule for cancer therapy. DBPR186 is a developmental drug candidate for delivering therapeutic agent, DM-1, that associates with PS.

Scroll to Top